StreetInsider.com News Articles

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Tue, 08 Sep 2026 14:43:58 -0400

Company Announcement

COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

4,409 shares at DKK 1,334.50,
1,464 shares at DKK 1,362.50,
20,270 shares at DKK 1,615.00, and
1,868 shares at DKK 1,948.00.

Proceeds to the Company are approximately DKK 44.3 million. The

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Tue, 08 Sep 2026 14:43:58 -0400

Company Announcement

COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

4,409 shares at DKK 1,334.50,
1,464 shares at DKK 1,362.50,
20,270 shares at DKK 1,615.00, and
1,868 shares at DKK 1,948.00.

Proceeds to the Company are approximately DKK 44.3 million. The

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Tue, 08 Sep 2026 06:00:00 -0400

Company Announcement

Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026

COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark.

The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached.

Shareholders are encouraged to visit Genmab’s website at Genmab.com for the Extraordinary General Meeting materials, including the notice and Shareholder

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Tue, 08 Sep 2026 06:00:00 -0400

Company Announcement

Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026

The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached.

Shareholders are encouraged to visit Genmab’s website at Genmab.com for the Extraordinary General Meeting materials, including the notice and Shareholder

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,900 at Barclays

Tue, 08 Sep 2026 05:38:36 -0400

Barclays analyst James Gordon raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,900.00 (from DKK2,500.00) while maintaining a Overweight rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,900 at Barclays

Tue, 08 Sep 2026 05:38:36 -0400

Barclays analyst James Gordon raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,900.00 (from DKK2,500.00) while maintaining a Overweight rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,900 at Barclays

Tue, 08 Sep 2026 05:38:36 -0400

Barclays analyst James Gordon raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,900.00 (from DKK2,500.00) while maintaining a Overweight rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,900 at Barclays

Tue, 08 Sep 2026 05:38:36 -0400

Barclays analyst James Gordon raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,900.00 (from DKK2,500.00) while maintaining a Overweight rating.

BofA Securities Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB)

Fri, 04 Sep 2026 06:06:46 -0400

BofA Securities analyst Sachin Jain reiterated a Buy rating and DKK2,500.00 price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB).

BofA Securities Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB)

Fri, 04 Sep 2026 06:06:46 -0400

BofA Securities analyst Sachin Jain reiterated a Buy rating and DKK2,500.00 price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB).

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank

Tue, 01 Sep 2026 04:44:53 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,500.00 (from DKK2,250.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank

Tue, 01 Sep 2026 04:44:53 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,500.00 (from DKK2,250.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank

Tue, 01 Sep 2026 04:44:53 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,500.00 (from DKK2,250.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank

Tue, 01 Sep 2026 04:44:53 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,500.00 (from DKK2,250.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 13:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26928260.html

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 13:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26928260.html

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 13:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26928260.html

Form 6-K GENMAB A/S For: Aug 12

Wed, 12 Aug 2026 09:49:00 -0400

si-local-file:///var/storage/secattach/20260812/26910259.html

Form 6-K GENMAB A/S For: Aug 12

Wed, 12 Aug 2026 09:49:00 -0400

si-local-file:///var/storage/secattach/20260812/26910259.html

Form 6-K GENMAB A/S For: Aug 12

Wed, 12 Aug 2026 09:49:00 -0400

si-local-file:///var/storage/secattach/20260812/26910259.html

Form 6-K GENMAB A/S For: Aug 11

Tue, 11 Aug 2026 14:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26904812.html

Form 6-K GENMAB A/S For: Aug 11

Tue, 11 Aug 2026 14:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26904812.html

Form 6-K GENMAB A/S For: Aug 11

Tue, 11 Aug 2026 14:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26904812.html

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Tue, 11 Aug 2026 13:53:35 -0400

Company Announcement

COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

4,702 shares at DKK 1,334.50,
2,069 shares at DKK 1,362.50, and
17,821 shares at DKK 1,615.00.

Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04%

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Tue, 11 Aug 2026 13:53:35 -0400

Company Announcement

COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

4,702 shares at DKK 1,334.50,
2,069 shares at DKK 1,362.50, and
17,821 shares at DKK 1,615.00.

Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04%